The LKB1-AMPK Pathway-Friend or Foe in Cancer?

    Research output: Contribution to journalEditorialpeer-review

    46 Citations (Scopus)

    Abstract

    Use of the biguanide metformin, an AMPK activator, is associated with a reduced incidence of cancer in diabetics, but it has been unclear whether this requires AMPK. In this issue of Cancer Cell, Shackelford and colleagues show, paradoxically, that biguanides are more effective in the treatment of mouse tumors that lack a functional LKB1-AMPK pathway.

    Original languageEnglish
    Pages (from-to)131-132
    Number of pages2
    JournalCancer Cell
    Volume23
    Issue number2
    Early online date11 Feb 2013
    DOIs
    Publication statusPublished - 11 Feb 2013

    Keywords

    • METFORMIN
    • AMPK
    • KINASE

    Cite this